Protocol Ledger

NCT06455410 · Phase II · RECRUITING

GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma

Interventional Phase II clinical trial protocol NCT06455410 sponsored by Sun Yat-sen University in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-18 Enrollment: 216 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06455410
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)216 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06455410
Protocol FieldVerified Registry Value
NCT IdentifierNCT06455410
Consolidated Lead SponsorSun Yat-sen University
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment216 participants (ESTIMATED)
Registered Start Date2024-06-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06455410
Hospital Research SiteLocationSite Profile
Sun Yat-sen Memorial HospitalGuangzhou, ChinaOpen Hospital Dossier ->
ZhuJiang Hospital of Southern Medical UniversityGuangzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI